Stem Cell Therapy for Arthritis: Types, Protocols, and What the Evidence Actually Shows

Stem cell therapy for arthritis has moved from fringe science to a legitimate clinical option in the past decade. It is still not a standard of care, and quality varies enormously depending on where you go and what cells are used. But for patients with moderate knee osteoarthritis or refractory rheumatoid arthritis who have exhausted conservative options, the evidence is good enough to warrant a serious conversation with a qualified provider.

This article covers what the science actually says, who is likely to benefit, what to expect from the procedure, and how to evaluate whether the cost is justified for your situation.

The Three Main Cell Sources

Not all stem cell injections are the same. The cell source matters enormously for both efficacy and cost. Here is what you need to know about each option.

Bone Marrow Concentrate (BMC)

BMC is drawn from the patient’s own iliac crest using a needle aspiration procedure done under local anesthesia. The aspirate is then spun in a centrifuge to concentrate mesenchymal stem cells (MSCs), platelets, and growth factors. The whole process takes about 90 minutes in a clinic setting.

BMC is considered an autologous, same-day procedure, which means it falls outside FDA regulations on more than minimal manipulation of cells. This keeps costs lower, typically $3,000 to $6,000, and no culture expansion is required. The tradeoff is that MSC concentration in bone marrow declines with age, so a 65-year-old may receive far fewer stem cells than a 40-year-old from the same volume of aspirate.

A 2020 randomized trial in The Journal of Bone and Joint Surgery (Shapiro et al., n=100) found that BMC injection improved KOOS pain scores by 25% at 12 months versus 16% for saline control in knee OA patients. The difference was statistically significant, though the clinical meaningfulness was debated.

Adipose-Derived Stromal Cells (ADSCs)

Fat tissue contains a high concentration of MSCs, roughly 2,500 times more per gram than bone marrow. Adipose-derived cells are harvested via a mini-liposuction procedure under local anesthesia, then processed in a centrifuge or enzymatic digestion to produce a stromal vascular fraction (SVF).

SVF contains not just MSCs but also endothelial progenitor cells, pericytes, and immune-modulating macrophages, which may contribute to its anti-inflammatory effects. The same-day SVF procedure costs $5,000 to $9,000. Culture-expanded ADSC products, which grow the cells in a lab to much higher numbers, require FDA IND approval and are available only in clinical trials or outside the US.

A 2019 study in Stem Cells Translational Medicine (Freitag et al., n=30) compared SVF injection to exercise therapy in knee OA. At 12 months, the SVF group had significantly better VAS pain scores and MRI cartilage assessment, though the study was small and the control arm was not ideal.

Umbilical Cord-Derived MSCs (UC-MSCs)

Cord-derived MSCs come from Wharton’s jelly, the gelatinous tissue inside umbilical cords donated after healthy births. These cells are allogeneic, meaning they come from a donor, not the patient. They are also younger, more proliferative, and more immunosuppressive than adult-derived MSCs.

Because they are processed and stored in advance, UC-MSC products can be administered as an off-the-shelf injection. However, FDA classification of these as more than minimally manipulated biologics means legitimate US clinical use is generally restricted to IND-approved trials. Products sold outside that framework are operating in a legal gray zone.

A 2021 RCT in Nature Medicine (Wang et al., n=115) using UC-MSCs in knee OA showed significant improvements in WOMAC scores at 12 months and dose-dependent effects, with higher cell counts producing better outcomes. Safety was favorable with no serious adverse events.

Clinical Evidence: Osteoarthritis vs. Rheumatoid Arthritis

Knee Osteoarthritis

Knee OA is the best-studied indication. A 2021 meta-analysis in Arthritis Research and Therapy (Yubo et al.) pooled 18 RCTs involving 1,016 patients and found that MSC injections produced significantly greater pain reduction and functional improvement than controls at 6 and 12 months. Effect sizes were moderate, comparable to what you see with hyaluronic acid but potentially more durable.

Importantly, disease stage matters. Kellgren-Lawrence grade 2 to 3 patients respond significantly better than grade 4. Once bone-on-bone disease is established, stem cells are not likely to regenerate enough cartilage to make a meaningful difference, and total knee replacement may be the more honest recommendation.

For hip OA, the evidence is thinner. A 2022 review in Cartilage found only 8 eligible studies, most with fewer than 50 patients. Results were generally positive but the data are too sparse to draw firm conclusions.

Rheumatoid Arthritis

RA is an autoimmune disease, and MSCs have immunosuppressive properties that make them theoretically well-suited for this condition. They suppress T-cell proliferation, reduce pro-inflammatory cytokines like TNF-alpha and IL-6, and promote regulatory T-cell activity.

A 2013 trial in Stem Cell Research and Therapy (Wang et al., n=136) enrolled RA patients who had failed disease-modifying antirheumatic drugs (DMARDs). UC-MSC infusions combined with continued DMARDs produced significantly better ACR improvement scores at 3 and 6 months compared to DMARDs alone. Remission rates were around 25% in the MSC group versus 5% in controls.

The evidence for RA is promising but thinner than for knee OA, and most trials used intravenous infusions rather than intra-articular injections, which is a different delivery model entirely.

Injection Protocols

For joint injections, ultrasound guidance is standard of care. Blind injections are less accurate and should not be accepted at this price point. The injection is typically placed in the suprapatellar pouch for knee procedures, with real-time imaging confirmation.

Most protocols use a single injection. Some clinics do a series of two to three injections spaced four to six weeks apart, particularly when combining stem cells with PRP (platelet-rich plasma). The evidence base for multi-injection protocols versus single-injection is not yet robust, and some physicians believe a single well-executed injection is preferable to diluting cells across multiple doses.

After injection, a standard protocol includes 48 to 72 hours of reduced activity, avoidance of anti-inflammatory medications for two to four weeks (as these can blunt the biological response), and a structured physical therapy program beginning at two weeks. Full return to activity typically takes four to six weeks.

Cost Breakdown

Insurance does not currently cover any form of stem cell therapy for arthritis outside of clinical trials. This is unlikely to change in the near term. Some flexible spending accounts (FSAs) or health savings accounts (HSAs) can be used, but verify with your plan administrator.

Who Is a Good Candidate

The ideal candidate for stem cell therapy for arthritis generally fits this profile: age 40 to 70, Kellgren-Lawrence grade 2 to 3 knee OA or moderate hip OA, has tried and failed physical therapy and cortisone injections, is not yet at the stage requiring joint replacement, and has realistic expectations.

Patients who are poor candidates include those with bone-on-bone disease (grade 4), active joint infection, uncontrolled autoimmune disease on high-dose immunosuppressants, active malignancy, or significant obesity (BMI over 40), as mechanical loading may overwhelm any biological repair.

For patients with osteoarthritis or chronic joint pain, stem cell therapy is one option within a broader treatment framework that should also address weight management, physical therapy, and activity modification. Cells alone rarely produce lasting results without addressing the biomechanical environment.

Recovery Timeline

Most patients experience a temporary flare of joint pain in the first one to three days post-injection, which is expected and reflects the inflammatory phase of healing. Significant improvement typically begins at six to eight weeks, though some patients report earlier changes.

Peak benefit is generally seen at six to twelve months. Data from longer follow-up studies suggest that results can persist for two years or more in responders, but repeat injections are sometimes needed at 18 to 24 months.

About 15 to 20% of patients are non-responders, meaning they see no meaningful benefit. This is a real consideration when evaluating whether to spend several thousand dollars on the procedure.

Red Flags When Evaluating Providers

Stem cell clinics vary enormously in quality, and some make claims that are not supported by science. Watch out for clinics that offer stem cell treatments for every condition imaginable, guarantee outcomes, use vague terms like “millions of stem cells” without specifying cell type or viability testing, or refuse to provide documentation of what is being injected.

Ask specifically: What cell source is being used? Is the product FDA-compliant for same-day use? Is the injection done under ultrasound guidance? What is the protocol for patients who do not respond? A qualified provider should answer these questions without hesitation.

Look for physicians with training in regenerative medicine, sports medicine, or orthopedics who can perform a proper musculoskeletal evaluation before recommending treatment. The injection should be part of a plan, not the whole plan.

Related Reading

• Joint Pain: Causes, Diagnosis, and the Full Treatment Spectrum
• Osteoarthritis: What It Is, Why It Progresses, and How Regenerative Medicine Is Changing Treatment
• PRP Therapy: How Platelet-Rich Plasma Works and What It Treats
• Rheumatoid Arthritis
• Stem Cell Therapy: Types, Evidence, Cost, Risks, and What You Need to Know